Targets › GJB2
1 program from 1 company in 1 trial: 1 Phase 1; Other; next expected readout Dec 2027.
Structural component of gap junctions. Gap junctions are dodecameric channels that connect the cytoplasm of adjoining cells. (UniProt, P29033)
Open in Phaseline: the race on GJB2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Skylark Bio | SKY-GJB2 Gene therapy replacing GJB2 (Connexin 26) | GJB2 | Phase 1 | GJB2-mediated Hearing Loss | Dec 2027 |
GJB2-mediated Hearing Loss (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.